*Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
†Department of Nephrology, Central University Hospital Dupuytren, Limoges, France
‡Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA
§Abteilung Klinische Chemie, Georg-August-Universität Göttingen, Germany
‡‡Department of Cardiac Surgery, University of Munich, Grosshadern Medical Center, Munich, Germany
§§University Children's Hospital, Heidelberg, Germany
∥Division of Cardiology, Tufts-New England Medical Center, Boston, MA
¶UCLA Department of Surgery, University of California, Los Angeles, CA
∥∥Mamelok Consulting, Palo Alto, CA
♯Analytical Unit, St George's University of London, London, UK
**Departments of Medicine and Pharmacology, University of Florida, Gainesville, FL
††Department of Nephrology and Renal Transplantation, University of Leuven, Belgium
This roundtable discussion meeting and preparation of this manuscript were supported by F Hoffmann-La Roche Ltd, Basel, Switzerland.
Reprints: Dr Teun van Gelder, Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands (e-mail: [email protected]).
Received for publication October 17, 2005; accepted November 22, 2005
All authors have previously acted as consultants or advisors for F Hoffmann-La Roche, among other pharmaceutical companies. Dr Holt is a consultant on the pharmacokinetics and bioanalytics of immunosuppressive drugs for Novartis, Roche, Wyeth, Astellas, Abbott Diagnostics, Microgenics, and Dade Behring.
